The Department of Endocrinology, 
Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health.
- Institute for Biomedical Research and Innovation, National Research Council, Palermo, Italy. Electronic address: elena.lopresti@cnr.it.
- Institute for Biomedical Research and Innovation, National Research Council, Palermo, Italy.
- Heart and Vascular Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates.
- Medical Research Center, Sultan Qaboos University, Muscat, Oman.
- Department of Training and Studies, Royal Hospital, Ministry of Health, Muscat, Oman.
- Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Poland
- Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland
- Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland.
- Department of Biochemistry, Mohamed Bin Rashid University, Dubai, United Arab Emirates.
- IRCCS MultiMedica, Milan, Italy.
- Clinic of Endocrinology, Ankara Güven Hospital, Ankara, Turkey.
- Unit of Cardiology, Karolinska Institute and Karolinska University Hospital, University of Stockholm, Sweden.
- Unit of Research and International Cooperation, University Hospital of Palermo, Italy.
- Department of Biomedicine, Neurosciences and Advanced Diagnostics (Bind), University of Palermo, Italy.
- Department of Endocrinology, Singapore General Hospital, Singapore.
- Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Slovenia.
- Department of Endocrinology, Bharti Hospital & BRIDE, Karnal, India.
- Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, India
- Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
- Department of Medicine and Oncology, Semmelweis University, Budapest, Hungary.
- The Research Institute, Imperial College London Diabetes Centre, Abu Dhabi, United Arab Emirates.
- Center for Clinical and Epidemiological Research, University Hospital, University of São Paulo, Brazil.
- Diabetes Center, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece.
- Department of Medicine, University of Central Florida College of Medicine, Orlando, FL, USA.
- Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
- Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
- Heart Institute (InCor) University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil
- Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
- Faculty of Medicine, Diabetes, Nutrition and Metabolic Diseases, Carol Davila University, Bucharest, Romania.
- Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Diabetes Research Centre, Chennai, India.
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), University of Palermo, Italy. Electronic address: manfredi.rizzo@unipa.it.
Biochimica et biophysica acta. Molecular basis of disease Vol. 1868 · Issue 12 · pp. 166559
PMID 36174875 DOI 10.1016/j.bbadis.2022.166559
Cite This Article
Elena Lo Presti, Domenico Nuzzo, Wael Al Mahmeed, Khalid Al-Rasadi, Kamila Al-Alawi, Maciej Banach, Yajnavalka Banerjee, Antonio Ceriello, Mustafa Cesur, Francesco Cosentino, Alberto Firenze, Massimo Galia, Su-Yen Goh, Andrej Janez, Sanjay Kalra, Nitin Kapoor, Peter Kempler, Nader Lessan, Paulo Lotufo, Nikolaos Papanas, Ali A Rizvi, Amirhossein Sahebkar, Raul D Santos, Anca P Stoian, Peter P Toth, Vijay Viswanathan, Manfredi Rizzo. Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health. Biochimica et biophysica acta. Molecular basis of disease. 2022;1868(12):166559. doi:10.1016/j.bbadis.2022.166559
Abstract
Obesity, type 2 diabetes (T2DM), hypertension (HTN), and Cardiovascular Disease (CVD) often cluster together as "Cardiometabolic Disease" (CMD). Just under 50% of patients with CMD increased the risk of morbidity and mortality right from the beginning of the COVID-19 pandemic as it has been reported in most countries affected by the SARS-CoV2 virus. One of the pathophysiological hallmarks of COVID-19 is the overactivation of the immune system with a prominent IL-6 response, resulting in severe and systemic damage involving also cytokines such as IL2, IL4, IL8, IL10, and interferon-gamma were considered strong predictors of COVID-19 severity. Thus, in this mini-review, we try to describe the inflammatory state, the alteration of the adipokine profile, and cytokine production in the obese state of infected and not infected patients by SARS-CoV2 with the final aim to find possible influences of COVID-19 on CMD and CVD. The immunological-based discussion of the molecular processes could inspire the study of promising targets for managing CMD patients and its complications during COVID-19.
Keywords
- COVID
- Cardiometabolic
- Diabetes
- Inflammation
- Molecular
